|
Feb 1, 2007
By:
Joanna Breitstein
Malaria kills nearly a million of Africa's youngest and most vulnerable every year. But budding partnerships are kicking the eradication mission into high gear, and creating new ways for pharma to get involved.
|
|
Dec 1, 2006
By:
Joanna Breitstein
Peter Rost, former Pfizer executive turned whistleblower, isn't just at war with his old employer. He's crusading against all of pharma, an industry he likens to the mob.
|
Variety is the spice of life—and the future of Big Pharma.
Nov 1, 2006
By:
Joanna Breitstein
When novartis had a look at its recent M&A activity, it found something unsettling: 70 percent of the deals it had done between 1996 and 2004 hadn't delivered their expected value to shareholders. Many other Big Pharmas are saddled with the same problem: The traditional pharmaceutical business model, by which prescription drug makers scoop up assets or companies similar to their own, is going nowhere fast.
|
|
And why not? Big Pharma's drugs fill Teva's pipeline. CEO Isræl Makov says he's not the enemy. To prove it, he offers lessons in survival.
Oct 1, 2006
By:
Joanna Breitstein
Isr?l makov has adventure in his blood. A fourth-generation Isr?li, he speaks proudly of his great grandmother, who bought and sold wool in Russia until the late 1890s when, at the age of 50, she moved to Palestine, bought a piece of land, and helped found a town in the wilderness. It was the kind of career move that Makov, CEO of Teva Pharmaceuticals, admires and emulates. As a boy, he rode a donkey to work in his father's orchards on the land his great grandmother bought. He attended an agricultural boarding school, started his career in citrus exports and—decades before Teva recruited him—managed Abic, the second-largest pharma company in Isr?l, and founded Interpharm, the country's first biotech company.
|
|
Preventive care is more efficient than treating disease after the fact. Now this paradigm takes hold in cancer.
May 1, 2006
By:
Joanna Breitstein
It's busy at merck these days— and not just in the Vioxx legal department. Instead, the entire office buzzes with activity: Executives work late hours, finalizing the regulatory submission; conference calls echo throughout the Whitehouse Station compound, dialed in to local affiliates around the world. In other offices, scientists write up scientific papers, while communications execs buzz in on intercoms, patching the flood of media calls to top scientists.
|
|
May 1, 2006
By:
Joanna Breitstein
Just how traditional marriages join a couple together from a common culture, Daiichi and Sankyo are merging based on a sense of having come from the same place, and facing the same future. But the art of integration lies in creating new ways of working that make the marriage bigger than the sum of its parts. Officiating the marriage is John Alexander, MD, head of pharma development for Daiichi Sankyo.
|
|
There are people who hope cancer, one day, will become a manageable disease. Then there are those who know it. Meet Susan Desmond-Hellmann.
Apr 1, 2006
By:
Joanna Breitstein
So-called "consumer-driven" health insurance is designed to help informed consumers make better decisions about their medical treatment. But the high deductibles associated with these plans are affecting the end goal.
|
|
Using Research to Understand a Changing Marketplace
Mar 1, 2006
By:
Joanna Breitstein, Patrick Clinton
Understanding how drugs are bought and paid for has always been a bit complicated. People used to say that pharma had two customers—physicians and patients. Only one of them used the drug, and neither of them knew the price. My, how times have changed. Now the industry has so many customers, it needs to stop and get to know them all over again. And that's at a time when drugs worth tens of billions of dollars are going off patent. To map pharma's shifting landscape, Pharm Exec convened a group of top market researchers to discuss the issues shaping an evolving industry. Topics ranged far and wide, from the advent of Medicare Part D, to the new focus on adherence, the role of international markets, even the brave new world of marketing to seniors' children.
|
|
Patient-Run Trials
Mar 1, 2006
By:
Joanna Breitstein
Companies don't have the budget, but are being forced to do more active surveillance.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
